Amarin Corporation plc News Releases https://investor.amarincorp.com/ Amarin Corporation plc News Releases en Amarin to Present at the 2019 BMO Prescription For Success Healthcare Conference https://investor.amarincorp.com/news-releases/news-release-details/amarin-present-2019-bmo-prescription-success-healthcare BEDMINSTER, N.J. and DUBLIN, Ireland, June 18, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Tue, 18 Jun 2019 07:00:16 -0400 Amarin Corporation plc News Releases 16996 Amarin to Present Findings Regarding Challenges of Current Treatment Options in Reducing Cardiovascular Risks for Diabetes Patients, Even for Those With Controlled Cholesterol Levels, at Annual American Diabetes Association (ADA) Meeting https://investor.amarincorp.com/news-releases/news-release-details/correcting-and-replacing-amarin-present-findings-regarding Approximately 10 Million People with Diabetes Are at Elevated Risk of  Cardiovascular Disease 1,2 In a release issued under the same headline earlier today by  Amarin Corporation plc (NASDAQ: AMRN), please note the copy has been updated to directly focus on Amarin’s presentations for the 2019 ADA Fri, 07 Jun 2019 10:55:00 -0400 Amarin Corporation plc News Releases 16986 Amarin to Present at the Goldman Sachs 40th Annual Global Healthcare Conference https://investor.amarincorp.com/news-releases/news-release-details/amarin-present-goldman-sachs-40th-annual-global-healthcare BEDMINSTER, N.J. and DUBLIN, Ireland, June 04, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Tue, 04 Jun 2019 06:00:09 -0400 Amarin Corporation plc News Releases 16956 Pharmaceutical Industry Veteran Gwen Fisher Joins Amarin to Lead Corporate Communications https://investor.amarincorp.com/news-releases/news-release-details/pharmaceutical-industry-veteran-gwen-fisher-joins-amarin-lead BEDMINSTER, N.J. and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Gwen Fisher has joined the company in a newly created role as vice president of Corporate Thu, 30 May 2019 07:00:31 -0400 Amarin Corporation plc News Releases 16921 Amarin to Present at the Jefferies 2019 Healthcare Conference https://investor.amarincorp.com/news-releases/news-release-details/amarin-present-jefferies-2019-healthcare-conference BEDMINSTER, N.J., and DUBLIN, Ireland, May 30, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that John F. Thu, 30 May 2019 05:00:10 -0400 Amarin Corporation plc News Releases 16911 U.S. FDA Grants Priority Review for Vascepa® (Icosapent Ethyl) Supplemental New Drug Application Seeking Cardiovascular Risk Reduction Indication https://investor.amarincorp.com/news-releases/news-release-details/us-fda-grants-priority-review-vascepar-icosapent-ethyl  - PDUFA date assigned is September 28, 2019, four months sooner than expected  - Vascepa , assuming approval, will be first drug indicated to reduce residual cardiovascular risk in patients with statin-managed LDL-C cholesterol, but persistent elevated triglycerides, as studied in the landmark Wed, 29 May 2019 06:00:21 -0400 Amarin Corporation plc News Releases 16896 Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting https://investor.amarincorp.com/news-releases/news-release-details/vascepar-be-featured-multiple-scientific-sessions-national-lipid Vascepa’s REDUCE-IT Trial Impact on Clinical Practice an Important Highlight BEDMINSTER, N.J. and DUBLIN, Ireland, May 16, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that Vascepa® (icosapent Thu, 16 May 2019 16:14:53 -0400 Amarin Corporation plc News Releases 16856 Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations https://investor.amarincorp.com/news-releases/news-release-details/amarin-reports-first-quarter-2019-financial-results-and-provides Total Revenue Increased 67% to $73.3 Million in First Quarter 2019 Compared to Prior Year Management to Host Conference Call at 7:30 a.m. ET Today BEDMINSTER, N.J., and DUBLIN, Ireland, May 01, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on Wed, 01 May 2019 05:00:11 -0400 Amarin Corporation plc News Releases 16711 New Drug Submission Filed for Vascepa® with Health Canada https://investor.amarincorp.com/news-releases/news-release-details/new-drug-submission-filed-vascepar-health-canada BEDMINSTER, N.J., and DUBLIN, Ireland, April 29, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that its licensee in Canada, HLS Therapeutics Inc. (TSX:HLS), has filed a New Drug Submission (“NDS”) Mon, 29 Apr 2019 06:00:19 -0400 Amarin Corporation plc News Releases 16691 Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019 https://investor.amarincorp.com/news-releases/news-release-details/amarin-report-first-quarter-2019-results-and-host-conference BEDMINSTER, N.J. and DUBLIN, Ireland, April 24, 2019 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), a pharmaceutical company focused on improving cardiovascular health, today announced that it will host a conference call with members of Amarin senior management to discuss the company's Wed, 24 Apr 2019 06:00:10 -0400 Amarin Corporation plc News Releases 16646